Recurrence Risk Reduced With AI vs Tamoxifen in Premenopausal ER+ Breast Cancer
This meta-analysis was conducted on data from 4 clinical trials including more than 7000 women with ER+ breast cancer.
This meta-analysis was conducted on data from 4 clinical trials including more than 7000 women with ER+ breast cancer.
The researchers found that targeted therapies matched to genomic alterations in ESCAT tier I/II significantly improved progression-free survival.
Palbociclib added to adjuvant endocrine therapy failed to improve iDFS.
Researchers evaluated outcomes for patients with breast cancer who were treated with a modern approach compared with a historical standard approach.
A subgroup analysis of the KEYNOTE-355 trial sought to determine which patients with metastatic TNBC would benefit from treatment with pembrolizumab and chemotherapy.
Improvements likely due to underlying genomic instability, increased sensitivity to DNA-damaging chemotherapy.
Although the combination was deemed active in HR-positive, HER2-negative disease, findings don’t support further research.
Combining neoadjuvant pembrolizumab with radiotherapy prior to standard of care chemotherapy may increase pathologic complete responses rates in TNBC.
The oncolytic virus pelareorep may mediate priming of an adaptive immune response in women with early breast cancer.
The majority of responses seen were ongoing at data cutoff.